Kymera Therapeutics reported a GAAP loss of $66.317 million for 9M 2021, doubling from $32.908 million in the previous year. Revenue increased 2.7 times to $57.557 million from $21.249 million a year earlier.
Warning BlackTerminal uses cookies in order to personalize and improve the usability of the service. If you do not want to use cookies, please change your browser settings. Accept